Journal article
A Single-Arm, Phase II Study of the Anti-Blys Monoclonal Antibody Belimumab in Symptomatic Waldenstrom Macroglobulinemia
Mark Bishton, Andrew Spencer, Michael Dickinson, David Ritchie
Clinical Lymphoma, Myeloma & Leukemia | CIG MEDIA GROUP, LP | Published : 2013
Grants
Funding Acknowledgements
We gratefully acknowledge the research support and provision of belimumab from Human Genome Sciences, (now fully owned by GlaxoSmithKline), which allowed us to complete this study.